TickerFacts.

Company research / ABCL

AbCellera Biologics Inc. (ABCL)

Build a valuation ↗↓ Download CSV

CIK 0001703057 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, AbCellera Biologics Inc. reported revenue of $75.13M. Revenue grew 160.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $66.17M.

Key ratios (year ended 2025-12-31)

-289.0%
Operating margin
-194.9%
Net margin
-15.1%
Return on year-end equity
160.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-24

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$66.17M$75.13M$28.83M$38.02M$485.42M$375.20M$233.16M$11.61M
R&D Expense$197.77M$186.83M$167.26M$175.66M$107.88M$62.06M$29.39M$10.11M
Operating Income-$225.16M-$217.10M-$314.77M-$237.21M$216.51M$204.41M$156.03M-$4.12M
Depreciation & Amortizationn/an/an/a$24.39M$27.84M$14.45M$4.84M$1.60M
EBITDAn/an/an/a-$212.81M$244.35M$218.86M$160.87M-$2.51M
Net Income-$164.66M-$146.41M-$162.86M-$146.40M$158.52M$153.46M$118.92M-$2.21M
EPS (Diluted)n/a-$0.49-$0.55-$0.51$0.50$0.48$0.45-$0.01
Total Assets$1.31B$1.36B$1.36B$1.49B$1.54B$1.32B$1.01Bn/a
Total Liabilities$411.56M$390.05M$304.47M$335.78M$307.63M$292.84M$175.03Mn/a
Shareholders' Equity$896.02M$966.90M$1.06B$1.15B$1.23B$1.03B$830.51M$10.25M
Cash & Equivalents$120.06M$128.51M$156.32M$133.32M$386.54M$476.14M$594.12Mn/a
Operating Cash Flow-$94.94M-$131.29M-$108.56M-$43.88M$277.36M$244.58M$22.69M$2.69M
Capital Expenditures$24.73M$42.77M$78.40M$76.95M$70.66M$58.45M$9.67M$4.00M
Free Cash Flow-$119.67M-$174.07M-$186.95M-$120.82M$206.70M$186.13M$13.02M-$1.30M
Shares Outstanding306.47M300.60M295.76M290.82M286.85M283.26M269.50Mn/a
Weighted Average Diluted Sharesn/a298.71M294.33M289.17M314.83M318.29M263.13M151.33M
EPS (Basic)n/a-$0.49-$0.55-$0.51$0.56$0.56$0.53-$0.01

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView